EXEL
Exelixis, Inc.
Price Chart
Latest Quote
$55.68
+0.13 (+0.23%)
Current Price
| Previous Close | $55.55 |
| Open | $55.55 |
| Day High | $56.75 |
| Day Low | $55.29 |
| Volume | 2,001,529 |
Stock Information
| Shares Outstanding | 251.36M |
| Total Debt | $169.54M |
| Cash Equivalents | $777.21M |
| Revenue | $2.38B |
| Net Income | $833.42M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $14.06B |
| P/E Ratio | 18.52 |
| EPS (TTM) | $3.02 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $13.45B |
| Sales | $2.38B |
| Income | $833.42M |
| Book/sh | $7.63 |
| Cash/sh | $3.09 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 3.01 |
| Current Ratio | 3.26 |
| Debt/Eq | 8.76 |
| EPS Growth TTM | 31.90% |
Returns & Margins
| ROA | 22.03% |
| ROE | 40.99% |
| Gross Margin | 96.44% |
| Operating Margin | 41.15% |
| Profit Margin | 35.08% |
Ownership
| Insider Ownership | 1.82% |
| Institutional Ownership | 106.74% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 14.12 |
| PEG | 2.56 |
| P/S | 5.92 |
| P/B | 7.33 |
Analyst Data
| Recommendation | buy |
| Target Price | $50.93 |
Technical Indicators
| SMA20 | $54.76 |
| SMA50 | $52.34 |
| SMA200 | $45.01 |
| RSI | 56.60 |
| ATR | 1.4950 |
| Shares Float | 204.45M |
| Short Float | 15.44% |
| Short Ratio | 10.18 |
| Volatility | 0.42 |
| Rel Volume | 0.86 |
Performance History
| Week | -1.03% |
| Month | +7.33% |
| Quarter | +26.00% |
| 6 Months | +23.63% |
| YTD | +28.32% |
| Year | +24.79% |
| 3 Years | +188.69% |
| 5 Years | +210.49% |
| 10 Years | +564.13% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $55.92 | 2,555,500 |
| 2026-07-16 | $55.68 | 2,031,000 |
| 2026-07-15 | $55.55 | 1,895,900 |
| 2026-07-14 | $55.77 | 1,799,500 |
| 2026-07-13 | $56.04 | 2,844,300 |
| 2026-07-10 | $56.50 | 3,219,800 |
| 2026-07-09 | $57.10 | 2,511,700 |
| 2026-07-08 | $56.11 | 1,783,200 |
| 2026-07-07 | $57.08 | 3,334,400 |
| 2026-07-06 | $55.53 | 3,143,400 |
| 2026-07-02 | $55.85 | 2,364,000 |
| 2026-07-01 | $53.96 | 1,843,200 |
| 2026-06-30 | $54.41 | 2,599,400 |
| 2026-06-29 | $54.28 | 2,587,700 |
| 2026-06-26 | $54.77 | 6,931,500 |
| 2026-06-25 | $53.23 | 2,256,200 |
| 2026-06-24 | $52.87 | 2,931,500 |
| 2026-06-23 | $51.34 | 2,574,400 |
| 2026-06-22 | $51.35 | 3,504,300 |
| 2026-06-18 | $51.91 | 6,545,200 |
About Exelixis, Inc.
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
đ° Latest News
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Zacks âĸ 2026-07-16T16:10:05Z
Is Exelixis (EXEL) Expensive After Its Recent Rally Or Still Undervalued?
Simply Wall St. âĸ 2026-07-11T18:07:09Z
Exelixis (EXEL) Stock Trades At A Discount After Its 236% Run
Simply Wall St. âĸ 2026-07-11T15:07:41Z
3 Under-the-Radar Stocks to Buy and Hold
Motley Fool âĸ 2026-07-10T18:50:00Z
EXEL Stock Soars 26.8% in Three Months: Is There More Room for Growth?
Zacks âĸ 2026-07-09T18:21:00Z
Is Exelixis, Inc. (EXEL) Among the Best Under-the-Radar Stocks to Invest In?
Insider Monkey âĸ 2026-07-08T19:20:32Z
EXEL vs. ILMN: Which Stock Should Value Investors Buy Now?
Zacks âĸ 2026-07-08T15:40:03Z
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
Zacks âĸ 2026-07-08T13:15:04Z
Sector Update: Healthcare Stocks Gain Thursday Afternoon
MT Newswires âĸ 2026-07-02T17:42:47ZExelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says
MT Newswires âĸ 2026-07-02T16:02:11Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $83,697,000 | $76,216,000 | $72,547,000 | $57,909,000 |
| Cost Of Revenue | $83,697,000 | $76,216,000 | $72,547,000 | $57,909,000 |
| Total Revenue | $2,320,126,000 | $2,168,701,000 | $1,830,208,000 | $1,611,062,000 |
| Operating Revenue | $3,209,129,000 | $2,877,552,000 | $2,473,862,000 | $2,160,988,000 |
| Expenses | ||||
| Total Expenses | $1,427,425,000 | $1,478,752,000 | $1,659,323,000 | $1,409,578,000 |
| Other Income Expense | $-20,708,000 | $-85,465,000 | $93,000 | $-197,000 |
| Other Non Operating Income Expenses | $-198,000 | $-133,000 | $93,000 | $-197,000 |
| Net Non Operating Interest Income Expense | $69,213,000 | $77,156,000 | $86,543,000 | $33,065,000 |
| Operating Expense | $1,343,728,000 | $1,402,536,000 | $1,586,776,000 | $1,351,669,000 |
| General And Administrative Expense | $518,727,000 | $492,128,000 | $542,705,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Net Interest Income | $69,213,000 | $77,156,000 | $86,543,000 | $33,065,000 |
| Interest Income | $69,213,000 | $77,156,000 | $86,543,000 | $33,065,000 |
| Normalized Income | $799,613,810 | $586,545,980 | $207,765,000 | $182,282,000 |
| Net Income From Continuing And Discontinued Operation | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Total Operating Income As Reported | $872,191,000 | $604,617,000 | $170,885,000 | $201,484,000 |
| Net Income Common Stockholders | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Net Income | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Net Income Including Noncontrolling Interests | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Net Income Continuous Operations | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Pretax Income | $941,206,000 | $681,640,000 | $257,521,000 | $234,352,000 |
| Special Income Charges | $-20,510,000 | $-85,332,000 | $0 | $0 |
| Interest Income Non Operating | $69,213,000 | $77,156,000 | $86,543,000 | $33,065,000 |
| Operating Income | $892,701,000 | $689,949,000 | $170,885,000 | $201,484,000 |
| Gross Profit | $2,236,429,000 | $2,092,485,000 | $1,757,661,000 | $1,553,153,000 |
| Per Share | ||||
| Diluted EPS | $2.78 | $1.76 | $0.65 | $0.56 |
| Basic EPS | $2.88 | $1.80 | $0.65 | $0.56 |
| Other | ||||
| Tax Effect Of Unusual Items | $-3,466,190 | $-20,053,020 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $942,266,000 | $804,084,000 | $196,602,000 | $222,359,000 |
| Total Unusual Items | $-20,510,000 | $-85,332,000 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-20,510,000 | $-85,332,000 | $0 | $0 |
| Reconciled Depreciation | $29,055,000 | $28,803,000 | $25,717,000 | $20,875,000 |
| EBITDA (Bullshit earnings) | $921,756,000 | $718,752,000 | $196,602,000 | $222,359,000 |
| EBIT | $892,701,000 | $689,949,000 | $170,885,000 | $201,484,000 |
| Diluted Average Shares | $281,863,000 | $296,132,000 | $321,464,000 | $324,556,000 |
| Basic Average Shares | $271,567,000 | $290,030,000 | $318,151,000 | $324,556,000 |
| Diluted NI Availto Com Stockholders | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Tax Provision | $158,636,000 | $160,373,000 | $49,756,000 | $52,070,000 |
| Impairment Of Capital Assets | $0 | $64,391,000 | $0 | $0 |
| Restructuring And Mergern Acquisition | $20,510,000 | $20,941,000 | $0 | $0 |
| Research And Development | $825,001,000 | $910,408,000 | $1,044,071,000 | $891,813,000 |
| Selling General And Administration | $518,727,000 | $492,128,000 | $542,705,000 | $459,856,000 |
| Other Gand A | $446,536,000 | $428,962,000 | $470,680,000 | - |
| Salaries And Wages | $72,191,000 | $63,166,000 | $72,025,000 | - |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,097,635,000 | $2,180,519,000 | $2,200,228,000 | $2,424,743,000 |
| Total Assets | $2,844,423,000 | $2,947,690,000 | $2,942,357,000 | $3,071,489,000 |
| Total Non Current Assets | $1,401,134,000 | $1,480,111,000 | $1,624,399,000 | $1,452,727,000 |
| Non Current Deferred Assets | $292,582,000 | $420,027,000 | $361,145,000 | $231,110,000 |
| Non Current Deferred Taxes Assets | $292,582,000 | $420,027,000 | $361,145,000 | $231,110,000 |
| Goodwill And Other Intangible Assets | $63,684,000 | $63,684,000 | $63,684,000 | $63,684,000 |
| Current Assets | $1,443,289,000 | $1,467,579,000 | $1,317,958,000 | $1,618,762,000 |
| Other Current Assets | $75,596,000 | $68,478,000 | $67,926,000 | $62,211,000 |
| Inventory | $21,686,000 | $22,388,000 | $17,323,000 | $33,299,000 |
| Receivables | $286,916,000 | $265,437,000 | $237,407,000 | $214,784,000 |
| Accounts Receivable | $286,916,000 | $265,437,000 | $237,407,000 | $214,784,000 |
| Cash Cash Equivalents And Short Term Investments | $1,059,091,000 | $1,111,276,000 | $995,302,000 | $1,308,468,000 |
| Cash And Cash Equivalents | $482,488,000 | $217,374,000 | $262,994,000 | $501,195,000 |
| Other Non Current Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $173,038,000 | $190,823,000 | $189,944,000 | $190,170,000 |
| Long Term Debt And Capital Lease Obligation | $173,038,000 | $190,823,000 | $189,944,000 | $190,170,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $683,104,000 | $703,487,000 | $678,445,000 | $583,062,000 |
| Total Non Current Liabilities Net Minority Interest | $277,460,000 | $299,718,000 | $284,168,000 | $258,703,000 |
| Other Non Current Liabilities | $104,422,000 | $108,895,000 | $94,224,000 | $68,533,000 |
| Current Liabilities | $405,644,000 | $403,769,000 | $394,277,000 | $324,359,000 |
| Other Current Liabilities | $125,382,000 | $95,012,000 | $108,417,000 | $78,924,000 |
| Payables And Accrued Expenses | $118,148,000 | $136,551,000 | $132,916,000 | $117,927,000 |
| Payables | $29,623,000 | $38,191,000 | $33,768,000 | $32,667,000 |
| Accounts Payable | $29,623,000 | $38,191,000 | $33,768,000 | $32,667,000 |
| Non Current Deferred Liabilities | - | - | - | $6,582,000 |
| Equity | ||||
| Common Stock Equity | $2,161,319,000 | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 |
| Total Equity Gross Minority Interest | $2,161,319,000 | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 |
| Stockholders Equity | $2,161,319,000 | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 |
| Gains Losses Not Affecting Retained Earnings | $3,476,000 | $-1,347,000 | $-3,750,000 | $-14,521,000 |
| Other Equity Adjustments | $3,476,000 | $-1,347,000 | $-3,750,000 | $-14,521,000 |
| Retained Earnings | $-76,830,000 | $-98,647,000 | $-173,351,000 | $-34,225,000 |
| Other | ||||
| Ordinary Shares Number | $262,483,000 | $281,732,000 | $302,793,000 | $323,951,000 |
| Share Issued | $262,483,000 | $281,732,000 | $302,793,000 | $323,951,000 |
| Tangible Book Value | $2,097,635,000 | $2,180,519,000 | $2,200,228,000 | $2,424,743,000 |
| Invested Capital | $2,161,319,000 | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 |
| Working Capital | $1,037,645,000 | $1,063,810,000 | $923,681,000 | $1,294,403,000 |
| Capital Lease Obligations | $173,038,000 | $190,823,000 | $189,944,000 | $190,170,000 |
| Total Capitalization | $2,161,319,000 | $2,244,203,000 | $2,263,912,000 | $2,488,427,000 |
| Additional Paid In Capital | $2,234,411,000 | $2,343,915,000 | $2,440,710,000 | $2,536,849,000 |
| Capital Stock | $262,000 | $282,000 | $303,000 | $324,000 |
| Common Stock | $262,000 | $282,000 | $303,000 | $324,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $173,038,000 | $190,823,000 | $189,944,000 | $190,170,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $102,218,000 | $109,830,000 | $93,325,000 | $77,158,000 |
| Current Provisions | $59,896,000 | $62,376,000 | $59,619,000 | $50,350,000 |
| Current Accrued Expenses | $88,525,000 | $98,360,000 | $99,148,000 | $85,260,000 |
| Investments And Advances | $603,603,000 | $637,291,000 | $728,717,000 | $756,731,000 |
| Goodwill | $63,684,000 | $63,684,000 | $63,684,000 | $63,684,000 |
| Net PPE | $441,265,000 | $359,109,000 | $470,853,000 | $401,202,000 |
| Accumulated Depreciation | $-132,228,000 | $-100,732,000 | $-80,390,000 | $-60,872,000 |
| Gross PPE | $573,493,000 | $459,841,000 | $551,243,000 | $462,074,000 |
| Leases | $111,087,000 | $108,277,000 | $89,038,000 | $83,334,000 |
| Construction In Progress | $3,003,000 | $2,875,000 | $24,465,000 | $4,933,000 |
| Other Properties | $418,595,000 | $310,153,000 | $393,026,000 | $330,184,000 |
| Machinery Furniture Equipment | $40,808,000 | $38,536,000 | $44,714,000 | $43,623,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $576,603,000 | $893,902,000 | $732,308,000 | $807,273,000 |
| Non Current Deferred Revenue | - | - | - | $6,582,000 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $844,339,000 | $633,786,000 | $170,355,000 | $224,158,000 |
| Operating Activities | ||||
| Operating Cash Flow | $884,267,000 | $699,971,000 | $333,324,000 | $362,614,000 |
| Cash Flow From Continuing Operating Activities | $884,267,000 | $699,971,000 | $333,324,000 | $362,614,000 |
| Investing Activities | ||||
| Capital Expenditure | $-39,928,000 | $-66,185,000 | $-162,969,000 | $-138,456,000 |
| Investing Cash Flow | $350,441,000 | $-116,783,000 | $-26,955,000 | $-524,414,000 |
| Cash Flow From Continuing Investing Activities | $350,441,000 | $-116,783,000 | $-26,955,000 | $-524,414,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-947,511,000 | $-652,033,000 | $-550,378,000 | $0 |
| Financing Cash Flow | $-969,594,000 | $-628,808,000 | $-546,052,000 | $586,000 |
| Cash Flow From Continuing Financing Activities | $-969,594,000 | $-628,808,000 | $-546,052,000 | $586,000 |
| Net Other Financing Charges | $-71,220,000 | $-38,625,000 | $-29,122,000 | $-23,300,000 |
| Net Common Stock Issuance | $-947,511,000 | $-652,033,000 | $-550,378,000 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $155,296,000 | $170,482,000 | $185,658,000 | $127,870,000 |
| End Cash Position | $482,488,000 | $217,374,000 | $262,994,000 | $502,677,000 |
| Beginning Cash Position | $217,374,000 | $262,994,000 | $502,677,000 | $663,891,000 |
| Changes In Cash | $265,114,000 | $-45,620,000 | $-239,683,000 | $-161,214,000 |
| Proceeds From Stock Option Exercised | $49,137,000 | $61,850,000 | $33,448,000 | $23,886,000 |
| Common Stock Payments | $-947,511,000 | $-652,033,000 | $-550,378,000 | $0 |
| Net Investment Purchase And Sale | $390,369,000 | $-50,598,000 | $136,014,000 | $-385,958,000 |
| Sale Of Investment | $1,022,866,000 | $877,307,000 | $1,038,482,000 | $1,064,758,000 |
| Purchase Of Investment | $-632,497,000 | $-927,905,000 | $-902,468,000 | $-1,450,716,000 |
| Net Intangibles Purchase And Sale | $-31,499,000 | $-37,750,000 | $-122,500,000 | $-110,750,000 |
| Purchase Of Intangibles | $-31,499,000 | $-37,750,000 | $-122,500,000 | $-110,750,000 |
| Net PPE Purchase And Sale | $-8,429,000 | $-28,435,000 | $-40,469,000 | $-27,706,000 |
| Purchase Of PPE | $-8,429,000 | $-28,435,000 | $-40,469,000 | $-27,706,000 |
| Change In Working Capital | $-191,197,000 | $-13,453,000 | $-13,973,000 | $-12,799,000 |
| Change In Payables And Accrued Expense | $-48,253,000 | $-22,035,000 | $51,451,000 | $-39,706,000 |
| Change In Accrued Expense | $1,899,000 | $-149,000 | $1,345,000 | $-63,065,000 |
| Change In Payable | $-50,152,000 | $-21,886,000 | $50,106,000 | $23,359,000 |
| Change In Account Payable | $-50,152,000 | $-21,886,000 | $50,106,000 | $23,359,000 |
| Change In Prepaid Assets | $-133,771,000 | $31,079,000 | $-29,824,000 | $-28,259,000 |
| Change In Inventory | $12,225,000 | $5,453,000 | $-12,977,000 | $-11,683,000 |
| Change In Receivables | $-21,398,000 | $-27,950,000 | $-22,623,000 | $66,849,000 |
| Changes In Account Receivables | $-21,398,000 | $-27,950,000 | $-22,623,000 | $66,849,000 |
| Other Non Cash Items | $24,619,000 | $64,585,000 | $140,679,000 | $125,040,000 |
| Stock Based Compensation | $112,983,000 | $93,836,000 | $106,345,000 | $107,574,000 |
| Asset Impairment Charge | $0 | $64,391,000 | $0 | $0 |
| Deferred Tax | $126,237,000 | $-59,458,000 | $-133,209,000 | $-60,358,000 |
| Deferred Income Tax | $126,237,000 | $-59,458,000 | $-133,209,000 | $-60,358,000 |
| Depreciation Amortization Depletion | $29,055,000 | $28,803,000 | $25,717,000 | $20,875,000 |
| Depreciation And Amortization | $29,055,000 | $28,803,000 | $25,717,000 | $20,875,000 |
| Net Income From Continuing Operations | $782,570,000 | $521,267,000 | $207,765,000 | $182,282,000 |
| Change In Other Working Capital | - | - | $-3,140,000 | $-2,483,000 |
| Depreciation | - | - | $25,717,000 | $20,875,000 |
Fetched: 2026-07-15